Inflammatory breast cancer is among one of the rarest and most deadly forms of breast cancer. It tends to strike younger women, is aggressive and difficult to treat. While current treatment options are limited, researchers at Jefferson have seen promising results from a new clinical study.
The drug currently being tested in a phase 1 clinical trial at Jefferson in combination with an approved chemotherapy, was originally used to treat a type of lymphoma. In early preclinical studies of inflammatory breast cancer, Dr. Cristofanilli and colleagues showed that the drug appeared to break up the clusters of cancer cells that cause inflammatory breast cancer, helping make the tumor cells more susceptible to chemotherapy.